Ian D Davis, MBBS, PhD is an expert in Oncology at Eastern Health (Australia). As of October 2026, ScienceLeadR ranks Ian D Davis in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Urologic Neoplasms. Ian D Davis has authored 701 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 2 of them ongoing. SLR score: 2,623 (community average: 125). How the SLR is computed.

LeadR Profile

Ian D Davis, MBBS, PhD Eastern Health Australia
2 623 ScienceLeadR Reputation 2623
Network Map

Oncology

Subspecialties: Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Professor Ian Davis MBBS(Hons) PhD FRACP FAChPM FAHMS GAICD is a medical oncologist and has been Professor of Medicine and Head of the Monash University Eastern Health Clinical School since 2012. He is an NHMRC Leadership Fellow L3. He also holds honorary appointments as an Affiliate Professor of Deakin University, adjunct Associate Professor of the University of Melbourne, Associate of the University of Sydney, Honorary Professorial Fellow with The George Institute, and Adjunct Professor of University of New South Wales. His primary clinical interests are in urologic cancers, and his primary research interests are in cancer immunology and the biology of urologic cancers. Prof Davis is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP, www.anzup.org.au), a not-for-profit charity dedicated to improving outcomes for people affected by “below the belt” cancers of the genitourinary system (prostate, kidney, bladder, testis, penis). Prof Davis is chair of the ANZUP Board and of its Scientific Advisory Committee, and Principal Investigator of several of its trials. He has been involved in over 220 clinical trials including over 130 as global or site Principal Investigator, and has published over 340 papers including over 240 of original research, with over 28,000 citations per Google Scholar.

Organizations

Career arc: 1991 - 2026

Source: PubMed

Monash University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 701

Citations

Citations: 41 900 1st author: 59 Last author: 108 Unique author: 23


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium.
PMID 41936190 — urinary bladder neoplasms, cells, growth, carcinoma, renal cell, prostatic neoplasms, therapeutics, prognosis
Clin Genitourin Cancer20260
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.
PMID 42048586 — single photon emission computed tomography computed tomography, neoplasms, prostate, radiology, tomography, emission-computed, single-photon, prostatic neoplasms, castration, therapeutics, survival rate
Radiology20260
Predictive value of early PSMA upregulation for the response to enzalutamide ±  177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.
PMID 41986500 — up-regulation, tomography, neoplasms, prostate, predictive value of tests, prostatic neoplasms, castration, therapeutics
Nat Cancer20260
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [ 177Lu] Lu-PSMA-617 (ANZUP1901).
PMID 41956861 — urology, tomography, neoplasms, prostate, positron emission tomography computed tomography, therapeutics
Eur Urol20260
Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025.
PMID 41766356 — neoplasms, prostate, prostatic neoplasms
Asia Pac J Clin Oncol20260

Clinical Studies 23

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 13
Phase 2 5
N/A 3
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 12
Active not recruiting 6
Recruiting 4
Unknown 1

By type:

Interventional 22
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 20

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Working Out M0 Bipolar Androgen Therapy
NCT06594926 — androgens, neoplasms, disease progression, prostate, testosterone, neoplasm metastasis, prostatic neoplasms, therapeutics
Phase 2Recruiting2024
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
NCT05881135 — choline, lung, cytidine, saline solution, cytidine diphosphate, lung injury, solutions, covid-19, therapeutics, cytidine diphosphate choline
Phase 1/Phase 2Active not recruiting2023

LeadR Networks

Main global connection map